UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2261-6
Program Prior Authorization/Medical Necessity
Medication Opzelura® (ruxolitinib)
P&T Approval Date 11/2021, 4/2022, 7/2022, 9/2022, 9/2023, 12/2024
Effective Date 3/1/2025
1. Background:
Opzelura (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the topical short term and non-
continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised
patients 12 years of age and older whose disease is not adequately controlled with topical prescription
therapies or when those therapies are not advisable. Opzelura is also indicated for the topical
treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors or potent
immunosuppressants such as azathioprine or cyclosporine is not recommended.
2. Coverage Criteriaa:
A. Atopic Dermatitis
1. Initial Authorization
a. Opzelura will be approved based on all of the following criteria:
(1) Diagnosis of mild to moderate atopic dermatitis
-AND-
(2) One of the following:
(a) History of failure, contraindication, or intolerance to two of the following
therapeutic classes of topical therapies^:
i. One of the following:
For mild atopic dermatitis: a topical corticosteroid [e.g., DesOwen
o
(desonide), hydrocortisone] (any potency)
For moderate atopic dermatitis: a topical corticosteroid of at least a
o
medium- to high-potency (e.g., Elocon (mometasone furoate),
Synalar (fluocinolone acetonide), Lidex (fluocinonide)]
ii. One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic
(tacrolimus)]*
iii. Eucrisa (crisaborole)*
-OR-
(b) Both of the following:
© 2024 UnitedHealthcare Services, Inc.
1
i. Patient is currently on Opzelura therapy
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the Incyte sponsored
Opzelura IncyteCARES program (e.g., sample card which can be
redeemed at a pharmacy for a free supply of medication) as a means to
establish as a current user of Opzelura¥
¥ Patients requesting initial authorization who were established on therapy via the receipt of
a manufacturer supplied sample at no cost in the prescriber’s office or any form of
assistance from the Incyte sponsored Opzelura IncyteCARES program shall be required to
meet initial authorization criteria as if patient were new to therapy.
-AND-
(3) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(4) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
2. Reauthorization
a. Opzelura will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to therapy
-AND-
(2) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(3) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
2
B. Nonsegmental Vitiligo
1. Initial Authorization
a. Opzelura will be approved based on all of the following criteria:
(1) Diagnosis of nonsegmental vitiligo
-AND-
(2) Other causes of depigmentation have been ruled out (e.g., nevus depigmentosus,
pityriasis alba, idiopathic guttate hypomelanosis, tinea (pityriasis) versicolor,
halo nevus, piebaldism, progressive macular hypomelanosis, lichen sclerosus,
chemical leukoderma, drug-induced leukoderma, hypopigmented mycosis
fungoides)
-AND-
(3) Affected areas not to exceed 10% body surface area
-AND-
(4) History of failure, contraindication, or intolerance to previous nonsegmental
vitiligo treatment(s) (e.g., topical corticosteroids, topical calcineurin inhibitors)
-AND-
(5) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(6) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
2. Reauthorization
a. Opzelura will be approved based all of the following criteria:
(1) Documentation of positive clinical response to therapy
-AND-
(2) Patient is not receiving Opzelura in combination with another biologic
medication [e.g., Dupixent (dupilumab), Xolair (omalizumab), Rituxan
(rituximab), Enbrel (etanercept), Avsola/Inflectra (infliximab)] or JAK inhibitor
© 2024 UnitedHealthcare Services, Inc.
3
[e.g., Jakafi (ruxolitinib), Xeljanz (tofacitinib), Rinvoq (upadacitinib)]
-AND-
(3) Patient is not receiving Opzelura in combination with a potent
immunosuppressant medication (e.g., azathioprine, cyclosporine)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
^ Tried/Failed alternative(s) are supported by FDA labeling
* Elidel, Protopic/tacrolimus ointment, and Eucrisa require prior authorization.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Opzelura [package insert]. Wilmington, DE: Incyte Corporation; August 2024.
2. Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. Am Fam Physician.
2020;101(10):590-598.
3. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic
dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am
Acad Dermatol. 2014;71(1):116-132.
4. Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European
Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5-19.
5. Grimes PE. Vitiligo: Management and prognosis. UpToDate. Waltham, MA: UpToDate Inc.
https://www.uptodate.com. Accessed on August 15, 2022.
6. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-592.
Program Prior Authorization/Medical Necessity - Opzelura (ruxolitinib)
Change Control
11/2021 New program.
4/2022 Changed initial authorization duration from 8 weeks to 12 months.
7/2022 Removed age requirement from criteria. Updated reference.
9/2022 Added coverage criteria for nonsegmental vitiligo. Updated
background, examples, and reference.
9/2023 Annual review with no change to clinical criteria. Updated reference.
12/2024 Annual review. Updated vitiligo initial authorization to 12 months.
Added FDA supported T/F footnote. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
4